The Truth Emerges On July 29, 2025, Novo issued a press release and held a conference call lowering its sales and profit outlook for 2025, citing "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." Management also noted that despite the expiry of the FDA grace period for mass compounding on May 22, 2025, company research showed that unsafe and unlawful mass compounding continued
Glucose sensing mediated by portal glucagon-like peptide 1 receptor is markedly impaired in insulin-resistant obese animals diabetes , 70, 99110
Neem - Animal feed study
Sometimes coverage depends on which medication your plan favors
However, their benefits are mild compared to the GLP-1 agonists (McIntyre RS et al, Am J Psychiatry 2024;181:2638)
Through their trusted relationships with patients, they can help patients manage their obesity-related conditions such as high blood pressure and joint disease, to name a few
